# US 2021/0261675 A1 · Chimeric antigen receptors based on single-domain antibodies and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0261675 A1
- Document ID: US20210261675A1
- Status: Published application
- Kind: A1
- Application number: 17/164,125
- Filed: 2021-02-01
- Published: 2021-08-26
- Earliest claimed: 2015-08-11
- Assignees: Legend Biotech USA Inc.
- Applicants: Legend Biotech USA Inc.
- Inventors: Xiaohu FAN; Chuan-Chu CHOU; Qiuchuan ZHUANG; Pingyan WANG; Lin WANG; Lei YANG; Jiaying HAO
- Web page: https://patentgrep.com/patent/US20210261675A1

## CPC

- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4211: {CD19 or B4}
- A61K 40/4215: {Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30}
- A61K 40/4221: {CD20}
- A61K 40/4222: {CD38 not IgG}
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07K 14/435: from animals; from humans
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70517: {CD8}
- C07K 14/70521: {CD28, CD152}
- C07K 14/70575: {NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154 (NGF C07K14/48, TNF C07K14/525)}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere}
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2887: {against CD20}
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- C07K 16/30: from tumour cells
- C07K 16/3061: {Blood cells}
- C07K 19/00: Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes}
- C12N 5/0636: {T lymphocytes}
- C12N 5/10: Cells modified by introduction of foreign genetic material
- C12N 15/62: DNA sequences coding for fusion proteins
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- A61K 2239/29: Multispecific CARs
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- C07K 2317/22: from camelids, e.g. camel, llama or dromedary
- C07K 2317/31: multispecific
- C07K 2317/35: Valency
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/21: containing a His-tag
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C12N 2510/00: Genetically modified cells
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present application provides single-domain antibodies, and chimeric antigen receptors comprising one or more antigen binding domains each comprising a single-domain antibody. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.

## Claims

### Claim at position 1

-43. (canceled)

### Claim 44

A chimeric antigen receptor (CAR) comprising a polypeptide comprising:
(a) an extracellular antigen binding domain comprising a first single-domain antibody (sdAb) specifically binding to a first antigen and a second single-domain antibody (sdAb) specifically binding to a second antigen, wherein each of the first and second sdAb is a VHH domain;
(b) a transmembrane domain; and
(c) an intracellular signaling domain.

### Claim 45 (depends on 44)

The CAR of claim 44, wherein the first antigen is different from the second antigen.

### Claim 46 (depends on 44)

The CAR of claim 44, wherein the first sdAb is located at the N-terminus of the second sdAb.

### Claim 47 (depends on 44)

The CAR of claim 44, wherein the first sdAb is located at the C-terminus of the second sdAb.

### Claim 48 (depends on 44)

The CAR of claim 44, wherein the first antigen and the second antigen are selected from the group consisting of CD19, CD20, CD22, CD33, CD38, BCMA, CS1, ROR1, GPC3, CD123, IL-13R, CD138, c-Met, EGFRvIII, GD-2, NY-ESO-1, MAGE A3, and glycolipid F77.

### Claim 49 (depends on 48)

The CAR of claim 48, wherein the first sdAb is an anti-BCMA sdAb.

### Claim 50 (depends on 48)

The CAR of claim 48, wherein the first sdAb is an anti-CD38 sdAb.

### Claim 51 (depends on 48)

The CAR of claim 48, wherein the first sdAb is an anti-CD19 sdAb.

### Claim 52 (depends on 48)

The CAR of claim 48, wherein the first sdAb is an anti-CD20 sdAb.

### Claim 53 (depends on 48)

The CAR of claim 48, wherein the first sdAb is an anti-CD22 sdAb.

### Claim 54 (depends on 48)

The CAR of claim 48, wherein the first sdAb is an anti-BCMA sdAb, and the second sdAb is an anti-CD38 sdAb.

### Claim 55 (depends on 48)

The CAR of claim 48, wherein the first sdAb is an anti-BCMA sdAb, and the second sdAb is an anti-CD19 sdAb.

### Claim 56 (depends on 48)

The CAR of claim 48, wherein the first sdAb is an anti-CD19 sdAb, and the second sdAb is an anti-CD20 sdAb.

### Claim 57 (depends on 48)

The CAR of claim 48, wherein the first sdAb is an anti-CD19 sdAb, and the second sdAb is an anti-CD22 sdAb.

### Claim 58 (depends on 44)

The CAR of claim 44, wherein the first antigen is the same as the second antigen.

### Claim 59 (depends on 58)

The CAR of claim 58, wherein the first sdAb and the second sdAb specifically bind to the same epitope.

### Claim 60 (depends on 58)

The CAR of claim 58, wherein the first sdAb and the second sdAb specifically bind to the different epitopes.

### Claim 61 (depends on 58)

The CAR of claim 58, wherein the first sdAb and the second sdAb bind to BCMA.

### Claim 62 (depends on 44)

The CAR of claim 44, wherein the first sdAb and/or the second sdAb are camelid, chimeric, human, or humanized.

### Claim 63 (depends on 44)

The CAR of claim 44, wherein the first sdAb and the second sdAb are directly fused to each other via a peptide bond.

### Claim 64 (depends on 44)

The CAR of claim 44, wherein the first sdAb and the second sdAb are fused to each other via a peptide linker.

### Claim 65 (depends on 64)

The CAR of claim 64, wherein the peptide linker is no more than 50 amino acids long.

### Claim 66 (depends on 44)

The CAR of claim 44, wherein the transmembrane domain is derived from a molecule selected from the group consisting of CD8α, CD4, CD28, CD137, CD80, CD86, CD152 and PD1.

### Claim 67 (depends on 44)

The CAR of claim 44, wherein the intracellular signaling domain comprises a primary intracellular signaling domain of an immune effector cell.

### Claim 68 (depends on 67)

The CAR of claim 67, wherein the primary intracellular signaling domain is derived from CD3ζ.

### Claim 69 (depends on 44)

The CAR of claim 44, wherein the intracellular signaling domain comprises a co-stimulatory signaling domain.

### Claim 70 (depends on 69)

The CAR of claim 69, wherein the co-stimulatory signaling domain is derived from a co-stimulatory molecule selected from the group consisting of CD27, CD28, CD137, OX40, CD30, CD40, CD3, LFA-1, CD2, CD7, LIGHT, NKG2C, B7-H3, Ligands of CD83 and combinations thereof.

### Claim 71 (depends on 44)

The CAR of claim 44, further comprising a hinge domain located between the C-terminus of the extracellular antigen binding domain and the N-terminus of the transmembrane domain.

### Claim 72 (depends on 44)

The CAR of claim 44, further comprising a signal peptide located at the N-terminus of the polypeptide.

### Claim 73 (depends on 44)

An isolated nucleic acid comprising a nucleic acid sequence encoding the CAR of claim 44.

### Claim 74 (depends on 73)

A vector comprising the isolated nucleic acid of claim 73.

### Claim 75 (depends on 44)

An engineered immune effector cell comprising the CAR of claim 44.

### Claim 76 (depends on 75)

The engineered immune effector cell of claim 75, wherein the immune effector cell is a T cell.

### Claim 77 (depends on 75)

A pharmaceutical composition comprising the engineered immune effector cell of claim 75, and a pharmaceutically acceptable carrier.

### Claim 78 (depends on 77)

A method of treating cancer in an individual, comprising administering to the individual an effective amount of the pharmaceutical composition of claim 77.
